Salisa C Westrick

Dr. Salisa C Westrick

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
MZMegan L. Zeek
Megan L. Zeek
MSMatthew J. Savoie
Matthew J. Savoie
MSMatthew Song
Matthew Song
LKLeanna M. Kennemur
Leanna M. Kennemur
JQJingjing Qian
Jingjing Qian
SWSalisa C Westrick
Salisa C Westrick
Objective. To identify sleep patterns and frequency of daytime sleepiness and to assess the association between sleep duration and academic performance among student pharmacists.Methods. A cross-sectional design was used. An anonymous self-administered paper questionnaire was administered to first-year through third-year students at a pharmacy school.Results. Questionnaires were completed by 364 student pharmacists (79.4% response rate and 93.8% cooperation rate). More than half of student pharmacists obtained less than 7 hours of sleep at night during a typical school week (54.7%) and a large majority on the night prior to an examination (81.7%). Almost half (47.8%) felt daytime sleepiness almost every day. Longer sleep duration the night prior to an examination was associated with higher course grades and semester grade point averages (GPAs).Conclusion. A majority of student pharmacists had suboptimal durations of sleep, defined as fewer than 7 hours. Adequate sleep the night prior to an examination was...

1 September 2018 in Vaccine
Verified
Journal Article
Open access
SWSalisa C Westrick
Salisa C Westrick
BPBrandon J. Patterson
Brandon J. Patterson
MKMohammad S. Kader
Mohammad S. Kader
SRSanuwar Rashid
Sanuwar Rashid
PBPhilip Buck
Philip Buck
MRMitchel C. Rothholz
Mitchel C. Rothholz
Pharmacists in the United States (U.S.) are authorized to administer vaccines. This study described: how and to what extent immunization services are offered, promoted, and documented in community pharmacies; reasons for referral to other locations for vaccination; and perceived barriers to immunization services. A mixed-mode (mail/electronic) survey of a stratified random sample of 1999 nationally-representative community pharmacies in the U.S. was conducted in April-July 2017. Survey instrument development was informed by validated scales and 10 in-depth interviews with community pharmacists; content and face validity were ensured via pre- (n = 5) and pilot-tests (n = 26) among community pharmacists. Potential non-response bias was investigated and descriptive statistics were used to analyze survey responses. Of the 1999 community pharmacies, 119 pharmacies were deemed ineligible. Of those eligible pharmacies, complete responses were provided by 292 respondents, each representing a unique pharmacy (15.5% response rate). Respondents were evenly split male/female (52.5/47.5%) and about half were pharmacy managers (51.3%). The majority (79.5%) reported offering at least one type of vaccine in 2016, with the most commonly administered vaccine types (average doses in 2016) being: Influenza (484), Pneumococcal 13-valent conjugate (55), Herpes Zoster (41), and Pneumococcal polysaccharide (39). Two-thirds (66.7%) of immunizing pharmacies provided adolescent vaccinations. Most frequently reported referral reasons were patients' insurance not covering vaccine administration at the pharmacy and patients' age not within approved protocol, policy or state law. The majority of respondents did not perceive organizational and environmental factors as barriers; however, they reported patient-related factors, especially cost and insurance coverage, as important barriers. The majority of U.S. community pharmacies reported offering at least one type of vaccine. The scope of pharmacy engagement in immunization services varied in terms of how and to what extent they were offered and documented. Addressing patient-related barriers is needed to further enhance pharmacy-based immunization services.

1 July 2013 in The International Journal of Psychiatry in Medicine
Verified
Journal Article
Closed access
RLRaymond A. Lorenz
Raymond A. Lorenz
MNMeghan M. Norris
Meghan M. Norris
LNLeah C. Norton
Leah C. Norton
SWSalisa C Westrick
Salisa C Westrick
Objective: To determine influenza (flu) vaccination status among the mentally ill population and identify factors associated with vaccination status. Method: A non-interventional, cross-sectional study was conducted. A self-administered survey to investigate the vaccination status and perceptions related to flu vaccine was administered between October 2011-January 2012 in an outpatient psychiatry clinic that served the indigent, severely mentally ill population of Alabama. All statistical analyses were based upon a significance level of 0.05. Results: Of the 736 patients invited, 302 participated (41%). Only 28.4% were vaccinated in 2010–2011 and 24.2% had been vaccinated at the time of the survey for 2011–2012. Respondents who had private health insurance, received a recommendation from healthcare providers, and who perceived a greater degree of vaccine effectiveness were more likely to obtain flu vaccination while respondents who had education beyond high school and were more in agreement that they can get the flu from the vaccine were less likely to obtain flu vaccination. All of the above factors accounted for 26.7% of vaccination decisions. Conclusions: The flu vaccination rate among this study's population was lower than the general population. Interventions targeting the above factors should help increase vaccination rates among the mentally ill population.

1 September 2014 in Vaccine
Verified
Journal Article
Closed access
BTBenjamin S. Teeter
Benjamin S. Teeter
KGKimberly Garza
Kimberly Garza
TST Lynn Stevenson
T Lynn Stevenson
MWMargaret A. Williamson
Margaret A. Williamson
MRMegan Roberts
Megan Roberts
SWSalisa C Westrick
Salisa C Westrick

1 September 2018 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
SWSaranrat Wittayanukorn
Saranrat Wittayanukorn
JQJingjing Qian
Jingjing Qian
SWSalisa C Westrick
Salisa C Westrick
NBNedret Billor
Nedret Billor
BJBrandon Johnson
Brandon Johnson
RHRichard A. Hansen
Richard A. Hansen
Purpose: Although clinical trials have provided some data on the benefit of angiotensin-converting enzyme inhibitors (ACEIs) or β-blockers (BBs) in patients with chemotherapy-induced cardiotoxicity, evidence of ACEIs/BBs on prevention of trastuzumab and/or anthracycline-induced cardiotoxicity outside trials is limited. Materials and Methods: A cohort study of 142,990 women (66 y and above) newly diagnosed with breast cancer from 2001 to 2009 was conducted using the Surveillance, Epidemiology, and End Results-Medicare–linked database. The ACEI/BB exposure was defined as filled prescription(s) before or after the initiation of trastuzumab/anthracyclines. The nonexposed group was defined as those who had never been prescribed ACEIs/BBs. Cumulative rates of cardiotoxicity and all-cause mortality were estimated and marginal structural Cox models were used to determine factors associated with cardiotoxicity and all-cause mortality adjusting for baseline covariates and use of chemotherapy. All statistical tests were 2 sided. Results: The final sample included 6542 women. Adjusted hazard ratio for cardiotoxicity and all-cause mortality for the ACEI/BB exposed group were 0.77 (95% confidence interval, 0.62-0.95) and 0.79 (95% confidence interval, 0.70-0.90) compared with the nonexposed group, respectively. Starting ACEIs/BBs≤6 months after the initiation of trastuzumab/anthracyclines and having exposed duration≥6 months were also associated with decreased risk of cardiotoxicity and all-cause mortality. Baseline characteristics, including age, non-Hispanic black, advanced cancer, region, comorbidity, preexisting cardiovascular conditions, lower socioeconomic status, and concomitant treatment were significantly associated with an elevated risk of all-cause mortality and/or cardiotoxicity (all P<0.05). Conclusions: ACEIs/BBs show favorable effects on preventing cardiotoxicity and improving survival in female breast cancer patients undergoing trastuzumab/anthracycline treatment.

1 June 2013 in Journal of Managed Care Pharmacy
Verified
Journal Article
Open access
SWSaranrat Wittayanukorn
Saranrat Wittayanukorn
SWSalisa C Westrick
Salisa C Westrick
RHRichard A. Hansen
Richard A. Hansen
NBNedret Billor
Nedret Billor
KBKimberly Braxton-Lloyd
Kimberly Braxton-Lloyd
KGKimberly B. Garza
Kimberly B. Garza
BACKGROUND: Cardiovascular disease (CVD) is a major cause of mortality in the United States, representing the highest total expenditures among major diseases. To improve CVD-associated outcomes, medication therapy management (MTM) services have been included in essential health benefit packages offered by various health plans. Nevertheless, the impact of such MTM services on outcomes is still unclear, especially from the perspective of the self-insured employer. OBJECTIVES: To (a) compare economic outcomes between patients who received and those who did not receive MTM services from the self-insured employer’s perspective and (b) compare clinical outcomes before and after receiving MTM services. METHODS: This study consisted of 2 pre- and post-retrospective designs: (1) a cohort study with comparison groups and (2) a cohort study within group comparison. Patients were beneficiaries aged 19 years or older who were diagnosed with CVD conditions according to ICD-9-CM codes and continuously enrolled in a publ...